Consistency in large pharmacogenomic studies

Nature

Volumn 540, Issue 7631, 2016, Pages E1-E2

  Geeleher, Paul ^a   Gamazon, Eric R ^a,b,c   Seoighe, Cathal ^d   Cox, Nancy J ^a,b   Huang, R Stephanie ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL1 PROTEIN; CRIZOTINIB; HYBRID PROTEIN; LAPATINIB; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; NILOTINIB; NUTLIN 3; SELUMETINIB; TANESPIMYCIN; UNCLASSIFIED DRUG;

BIOASSAY; CANCER; CELLS AND CELL COMPONENTS; DATA SET; DRUG DEVELOPMENT; GENE EXPRESSION; GENOMICS; PROJECT ASSESSMENT;

AREA UNDER THE CURVE; BIOASSAY; CANCER CELL LINE; CHEMOSENSITIVITY; CORRELATION COEFFICIENT; DRUG RESPONSE; DRUG SENSITIVITY; FUSION GENE; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; PHARMACOGENOMICS; PRIORITY JOURNAL; SHORT SURVEY;

EID: 85000893979     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature19838     Document Type: Short Survey

References (15)

1. Geeleher, P., Gamazon, E. R., Seoighe, C., Cox, N. J. & Huang, R. S. Consistencyin large pharmacogenomic studies. Nature 540, http://dx.doi.org/10.1038/nature19838 (2016).
2. Garnett, M. J. et al. Systematic identification of genomic markers of drugsensitivity in cancer cells. Nature 483, 570-575 (2012).
3. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictivemodelling of anticancer drug sensitivity. Nature 483, 603-607 (2012).
4. Haibe-Kains, B. et al. Inconsistency in large pharmacogenomic studies. Nature504, 389-393 (2013).
5. Safikhani, Z. et al. Revisiting inconsistency in large pharmacogenomic studies.F1000Research http://dx.doi.org/10.12688/f1000research.9611.1 (2016).
6. Haverty, P. M. et al. Reproducible pharmacogenomic profiling of cancer cell linepanels. Nature 533, 333-337 (2016).
7. The Cancer Cell Line Encyclopedia Consortium and Genomics of DrugSensitivity in Cancer Investigators. Pharmacogenomic agreement between twocancer cell line data sets. Nature 528, 84-87 (2015).
8. Matthews, B. W. Comparison of the predicted and observed secondarystructure of T4 phage lysozyme. Biochim. Biophys. Acta 405, 442-451 (1975).
9. Geeleher, P., Cox, N. J. & Huang, R. S. Clinical drug response can be predictedusing baseline gene expression levels and in vitro drug sensitivity in cell lines.Genome Biol. 15, R47 (2014).
10. Papillon-Cavanagh, S. et al. Comparison and validation of genomic predictorsfor anticancer drug sensitivity. J. Am. Med. Inform. Assoc. 20, 597-602(2013).
11. Dong, Z. et al. Anticancer drug sensitivity prediction in cell lines from baselinegene expression through recursive feature selection. BMC Cancer 15, 489(2015).
12. Jang, I. S., Neto, E. C., Guinney, J., Friend, S. H. & Margolin, A. A. Systematicassessment of analytical methods for drug sensitivity prediction from cancercell line data. Pac. Symp. Biocomput. 2014, 63-74 (2014).
13. Cortés-Ciriano, I. et al. Improved large-scale prediction of growth inhibitionpatterns using the NCI60 cancer cell line panel. Bioinformatics 32, 85-95(2015).
14. Goodspeed, A., Heiser, L. M., Gray, J. W. & Costello, J. C. Tumor-derived cell linesas molecular models of cancer pharmacogenomics. Mol. Cancer Res. 14, 3-13(2015).
15. Sandve, G. K, Nekrutenko, A., Taylor, J. & Hovig, E. Ten simple rules forreproducible computational research. PLoS Comput. Biol. 9, e1003285 (2013).